Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
What is your current preferred approach in the management of metasatic sarcomatoid NSCLC?
Specifically, would carbo-taxol-bev-atezo (IMpower 150) be an attractive option given the activity of bev-atezo in sarcomatoid PDL1+ metastatic RCC (IMmotion 151)?
Answer from: Medical Oncologist at Academic Institution
This is certainly a very relevant question not just as to the proper management of pulmonary sarcomatoid carcinoma but also other rare cancer subtypes in general where it is hard to know how to properly utilize information obtained on more common subtypes of the same malignancy. Many times we have t...
Sign in or Register to read more